These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 34807395)

  • 1. Value of
    de Mooij CM; Mitea C; Mottaghy FM; Smidt ML; van Nijnatten TJA
    EJNMMI Res; 2021 Nov; 11(1):116. PubMed ID: 34807395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subtype-Guided
    Wu S; Wang Y; Li J; Zhang N; Mo M; Klimberg S; Kaklamani V; Cochet A; Shao Z; Cheng J; Liu G
    Oncologist; 2020 Apr; 25(4):e626-e633. PubMed ID: 32297448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additional value of
    van Ramshorst MS; Teixeira SC; Koolen BB; Pengel KE; Gilhuijs KG; Wesseling J; Rodenhuis S; Valdés Olmos RA; Rutgers EJ; Vogel WV; Sonke GS; Vrancken Peeters MT
    Cancer Imaging; 2017 May; 17(1):15. PubMed ID: 28545563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2- Breast Cancer.
    Groheux D; Sanna A; Majdoub M; de Cremoux P; Giacchetti S; Teixeira L; Espié M; Merlet P; de Roquancourt A; Visvikis D; Hatt M; Resche-Rigon M; Hindié E
    J Nucl Med; 2015 Jun; 56(6):824-31. PubMed ID: 25883123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Axillary lymph node response to neoadjuvant systemic therapy with dedicated axillary hybrid
    de Mooij CM; Samiei S; Mitea C; Lobbes MBI; Kooreman LFS; Heuts EM; Beets-Tan RGH; van Nijnatten TJA; Smidt ML
    Clin Radiol; 2022 Oct; 77(10):e732-e740. PubMed ID: 35850866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour 18 F-FDG Uptake on preoperative PET/CT may predict axillary lymph node metastasis in ER-positive/HER2-negative and HER2-positive breast cancer subtypes.
    Kim JY; Lee SH; Kim S; Kang T; Bae YT
    Eur Radiol; 2015 Apr; 25(4):1172-81. PubMed ID: 25298170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined
    Wu J; Zhang X; Jia Z; Zhou X; Qi R; Ji H; Sun J; Sun C; Teng Z; Lu G; Chen X
    Mol Pharm; 2022 Sep; 19(9):3405-3411. PubMed ID: 35972444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Major Reduction in Axillary Lymph Node Dissections After Neoadjuvant Systemic Therapy for Node-Positive Breast Cancer by combining PET/CT and the MARI Procedure.
    van der Noordaa MEM; van Duijnhoven FH; Straver ME; Groen EJ; Stokkel M; Loo CE; Elkhuizen PHM; Russell NS; Vrancken Peeters MTFD
    Ann Surg Oncol; 2018 Jun; 25(6):1512-1520. PubMed ID: 29511992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic accuracy of dual-time-point 18F-FDG PET/CT for the detection of axillary lymph node metastases in breast cancer patients.
    Hahn S; Hecktor J; Grabellus F; Hartung V; Pöppel T; Kimmig R; Forsting M; Antoch G; Heusner TA
    Acta Radiol; 2012 Jun; 53(5):518-23. PubMed ID: 22547387
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Groheux D; Martineau A; Teixeira L; Espié M; de Cremoux P; Bertheau P; Merlet P; Lemarignier C
    Breast Cancer Res; 2017 Jan; 19(1):3. PubMed ID: 28057031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility of FDG PET/CT to monitor the response of axillary lymph node metastases to neoadjuvant chemotherapy in breast cancer patients.
    Straver ME; Aukema TS; Olmos RA; Rutgers EJ; Gilhuijs KG; Schot ME; Vogel WV; Peeters MJ
    Eur J Nucl Med Mol Imaging; 2010 Jun; 37(6):1069-76. PubMed ID: 20130860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment.
    Groheux D; Giacchetti S; Hatt M; Marty M; Vercellino L; de Roquancourt A; Cuvier C; Coussy F; Espié M; Hindié E
    Br J Cancer; 2013 Sep; 109(5):1157-64. PubMed ID: 23942075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparing prediction performances of
    Vincent L; Jankowski C; Arnould L; Coudert B; Rouzier R; Reyal F; Humbert O; Coutant C
    Gynecol Obstet Fertil Senol; 2020 Sep; 48(9):679-686. PubMed ID: 32205278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic Performance of Noninvasive Imaging for Assessment of Axillary Response After Neoadjuvant Systemic Therapy in Clinically Node-positive Breast Cancer: A Systematic Review and Meta-analysis.
    Samiei S; de Mooij CM; Lobbes MBI; Keymeulen KBMI; van Nijnatten TJA; Smidt ML
    Ann Surg; 2021 Apr; 273(4):694-700. PubMed ID: 33201095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer.
    Koolen BB; Pengel KE; Wesseling J; Vogel WV; Vrancken Peeters MJ; Vincent AD; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Valdés Olmos RA
    Breast; 2013 Oct; 22(5):691-7. PubMed ID: 23414930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the diagnostic value of FDG-PET/CT and axillary ultrasound for the detection of lymph node metastases in breast cancer patients.
    Riegger C; Koeninger A; Hartung V; Otterbach F; Kimmig R; Forsting M; Bockisch A; Antoch G; Heusner TA
    Acta Radiol; 2012 Dec; 53(10):1092-8. PubMed ID: 23002144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Value of Semiquantitative Parameters Derived from
    Urso L; Evangelista L; Alongi P; Quartuccio N; Cittanti C; Rambaldi I; Ortolan N; Borgia F; Nieri A; Uccelli L; Schirone A; Panareo S; Arnone G; Bartolomei M
    Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.
    Cheng J; Wang Y; Mo M; Bao X; Zhang Y; Liu G; Zhang J; Geng D
    Oncotarget; 2015 Oct; 6(30):29388-95. PubMed ID: 26336821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of FDG PET/CT to Evaluation of Axillary Lymph Nodes after Neoadjuvant Chemotherapy in Breast Cancer.
    Simsek ET; Coban E; Atag E; Gungor S; Sari M; Gurleyik G
    J Coll Physicians Surg Pak; 2021 Jul; 31(7):792-797. PubMed ID: 34271778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from ⁶⁸Ga-RGD PET/CT and ¹⁸F-FDG PET/CT.
    Yoon HJ; Kang KW; Chun IK; Cho N; Im SA; Jeong S; Lee S; Jung KC; Lee YS; Jeong JM; Lee DS; Chung JK; Moon WK
    Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1534-43. PubMed ID: 24652232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.